Table 1 Comparison of clinicopathological profiles between low and high TRIP13 expression in CRC patients

From: TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer

 

Low expression (n = 89)

High expression (n = 111)

p

 

n

%

n

%

 

Age

    

0.294

 <60

31

34.8

31

27.9

 

 ≥60

58

65.2

80

72.1

 

Gender

    

0.938

Female

38

42.7

48

43.2

 

Male

51

57.3

63

56.8

 

Tumor location

    

0.709

Rectal

27

30.3

31

27.9

 

Colon

62

69.7

80

72.1

 

Tumor size

    

0.884

 <15 cm3

28

31.5

36

32.4

 

 ≥15 cm3

61

68.5

75

67.6

 

Differentiation

    

0.49

Poor

18

20.2

27

24.3

 

Moderate & well

71

79.8

84

75.7

 

pTNM

    

0.005**

I-II

49

55.1

39

35.1

 

III-IV

40

44.9

72

64.9

 

CEA

    

0.045*

<5 μg/l

59

66.3

58

52.3

 

≥5 μg/l

30

33.7

53

47.7

 

CA125

    

0.378

<35 U/ml

66

74.2

76

68.5

 

 ≥35 U/ml

23

25.8

35

31.5

 

CA19-9

    

0.043*

<37 U/ml

68

76.4

70

63.1

 

≥37 U/ml

21

23.6

41

36.9

 
  1. Chi-square test was performed, and p < 0.05 was considered statistically significantly. *p < 0.05; **p < 0.01
  2. pTNM pathological tumor, lymph node, metastasis classification, CEA carcino-embryonic antigen, CA125 carbohydrate antigen-125, CA19-9 carbohydrate antigen-19-9
Back to article page